Hypertension - aspirin

Since the magnitude of benefit from the reduction in cardiovascular events was similar to the magnitude of harm of an increased risk of haemorrhagic events, the Cochrane review concluded that antiplatelet therapy with aspirin cannot be recommended in uncomplicated hypertension as primary prevention per se due to the narrow balance between benefit and harm.